JP2016537431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537431A5 JP2016537431A5 JP2016554826A JP2016554826A JP2016537431A5 JP 2016537431 A5 JP2016537431 A5 JP 2016537431A5 JP 2016554826 A JP2016554826 A JP 2016554826A JP 2016554826 A JP2016554826 A JP 2016554826A JP 2016537431 A5 JP2016537431 A5 JP 2016537431A5
- Authority
- JP
- Japan
- Prior art keywords
- obese
- pharmaceutical formulation
- pharmaceutical
- formulation according
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 230000014101 glucose homeostasis Effects 0.000 claims description 8
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- -1 -COOR 8) Chemical class 0.000 claims description 6
- 238000006845 Michael addition reaction Methods 0.000 claims description 6
- 210000000577 adipose tissue Anatomy 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 235000013877 carbamide Nutrition 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 150000002825 nitriles Chemical class 0.000 claims description 6
- 150000003568 thioethers Chemical class 0.000 claims description 6
- 102000016267 Leptin Human genes 0.000 claims description 4
- 108010092277 Leptin Proteins 0.000 claims description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- BYUYRWRYAISPPF-UHFFFAOYSA-N cyclobutyloxycyclobutane Chemical compound C1CCC1OC1CCC1 BYUYRWRYAISPPF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 235000012631 food intake Nutrition 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 238000007306 functionalization reaction Methods 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229940039781 leptin Drugs 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 208000016261 weight loss Diseases 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 206010007134 Candida infections Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 235000021316 daily nutritional intake Nutrition 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 150000003140 primary amides Chemical class 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000003334 secondary amides Chemical class 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 claims description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 150000003672 ureas Chemical class 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims 9
- 235000020824 obesity Nutrition 0.000 claims 6
- 208000012696 congenital leptin deficiency Diseases 0.000 claims 3
- 208000001022 morbid obesity Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908998P | 2013-11-26 | 2013-11-26 | |
| US61/908,998 | 2013-11-26 | ||
| PCT/US2014/067393 WO2015081093A1 (en) | 2013-11-26 | 2014-11-25 | Compounds for the treatment of obesity and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019226600A Division JP2020059744A (ja) | 2013-11-26 | 2019-12-16 | 肥満を処置するための化合物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537431A JP2016537431A (ja) | 2016-12-01 |
| JP2016537431A5 true JP2016537431A5 (OSRAM) | 2017-11-24 |
| JP6672157B2 JP6672157B2 (ja) | 2020-03-25 |
Family
ID=52134396
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554826A Active JP6672157B2 (ja) | 2013-11-26 | 2014-11-25 | 肥満を処置するための化合物およびその使用方法 |
| JP2019226600A Pending JP2020059744A (ja) | 2013-11-26 | 2019-12-16 | 肥満を処置するための化合物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019226600A Pending JP2020059744A (ja) | 2013-11-26 | 2019-12-16 | 肥満を処置するための化合物およびその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160375039A1 (OSRAM) |
| EP (1) | EP3074033B1 (OSRAM) |
| JP (2) | JP6672157B2 (OSRAM) |
| AU (2) | AU2014354831B2 (OSRAM) |
| CA (1) | CA2931826C (OSRAM) |
| CY (1) | CY1122551T1 (OSRAM) |
| DK (1) | DK3074033T3 (OSRAM) |
| ES (1) | ES2709976T3 (OSRAM) |
| HR (1) | HRP20190219T1 (OSRAM) |
| HU (1) | HUE042196T2 (OSRAM) |
| LT (1) | LT3074033T (OSRAM) |
| PL (1) | PL3074033T3 (OSRAM) |
| PT (1) | PT3074033T (OSRAM) |
| RS (1) | RS58422B1 (OSRAM) |
| SI (1) | SI3074033T1 (OSRAM) |
| SM (1) | SMT201900064T1 (OSRAM) |
| TR (1) | TR201901299T4 (OSRAM) |
| WO (1) | WO2015081093A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015153933A1 (en) * | 2014-04-03 | 2015-10-08 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| CN106008657B (zh) * | 2016-05-20 | 2017-11-21 | 天津中医药大学 | 苦蘵苦素i及提取方法及用途 |
| IT201800005336A1 (it) * | 2018-05-14 | 2019-11-14 | Composizioni per uso nel trattamento dell’obesità | |
| WO2021072139A1 (en) * | 2019-10-11 | 2021-04-15 | Massachusetts Institute Of Technology | Formulations for gastrointestinal delivery of oligonucleotides |
| CN113599502A (zh) * | 2021-07-22 | 2021-11-05 | 廖儒佳 | 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA791659B (en) | 1978-04-17 | 1980-04-30 | Ici Ltd | Process and apparatus for spraying liquid |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996040912A1 (en) | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
| IL122718A0 (en) | 1995-06-30 | 1998-08-16 | Lilly Co Eli | Methods for treating diabetes |
| EP0865294B1 (en) | 1995-08-17 | 2004-02-18 | Amgen Inc. | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| ES2217327T3 (es) | 1995-11-22 | 2004-11-01 | Amgen Inc., | Proteina ob para aumentar la masa de tejido magro. |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| WO1997038014A1 (en) | 1996-04-04 | 1997-10-16 | Amgen Inc. | Fibulin pharmaceutical compositions and related methods |
| CA2258504A1 (en) * | 1996-06-20 | 1997-12-24 | Merck & Co., Inc. | Gene therapy for obesity |
| JP2001501177A (ja) | 1996-08-30 | 2001-01-30 | アムジエン・インコーポレーテツド | Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法 |
| BR9711513A (pt) | 1996-09-20 | 1999-08-24 | Hoechst Ag | Uso de antagonistas de leptina para o tratamento de resistencia a insulina em diabete do tipo ii |
| EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| EA004790B1 (ru) | 1996-12-20 | 2004-08-26 | Амген Инк. | Композиции на основе слитого белка ов и способы их применения |
| ATE223229T1 (de) | 1997-04-17 | 2002-09-15 | Amgen Inc | Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren |
| TR199902980T2 (xx) | 1997-06-06 | 2000-05-22 | Smithkline Beecham P.L.C. | Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�. |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| PT1107793E (pt) | 1998-08-10 | 2005-02-28 | Amgen Inc | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados |
| AU6396999A (en) | 1998-10-02 | 2000-04-26 | Amgen, Inc. | Method to determine a predisposition to leptin treatment |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| CA2359840C (en) | 1999-02-12 | 2012-10-23 | Amgen Inc. | Glycosylated leptin compositions and related methods |
| PL214862B1 (pl) | 2001-10-22 | 2013-09-30 | Amgen | Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny |
| WO2004039832A2 (en) | 2002-10-31 | 2004-05-13 | Albany Medical College | Leptin-related peptides |
| JP4585186B2 (ja) * | 2003-07-31 | 2010-11-24 | 杏林製薬株式会社 | 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤 |
| JP2009541423A (ja) * | 2006-06-23 | 2009-11-26 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ |
| US20110230551A1 (en) * | 2008-09-15 | 2011-09-22 | Leslie Gunatilaka | Withaferin a analogs and uses thereof |
| WO2010053655A2 (en) * | 2008-11-07 | 2010-05-14 | University Of Kansas | Therapeutic methods with withaferin a and analogs |
| US8598339B2 (en) * | 2011-02-01 | 2013-12-03 | University Of Kansas | Withanolide isolated from Physalis longifolia and analogs and methods of use thereof |
-
2014
- 2014-11-25 TR TR2019/01299T patent/TR201901299T4/tr unknown
- 2014-11-25 RS RS20190124A patent/RS58422B1/sr unknown
- 2014-11-25 ES ES14816018T patent/ES2709976T3/es active Active
- 2014-11-25 LT LTEP14816018.7T patent/LT3074033T/lt unknown
- 2014-11-25 HR HRP20190219TT patent/HRP20190219T1/hr unknown
- 2014-11-25 SM SM20190064T patent/SMT201900064T1/it unknown
- 2014-11-25 JP JP2016554826A patent/JP6672157B2/ja active Active
- 2014-11-25 AU AU2014354831A patent/AU2014354831B2/en not_active Ceased
- 2014-11-25 PL PL14816018T patent/PL3074033T3/pl unknown
- 2014-11-25 HU HUE14816018A patent/HUE042196T2/hu unknown
- 2014-11-25 US US15/039,743 patent/US20160375039A1/en not_active Abandoned
- 2014-11-25 PT PT14816018T patent/PT3074033T/pt unknown
- 2014-11-25 EP EP14816018.7A patent/EP3074033B1/en active Active
- 2014-11-25 SI SI201431046T patent/SI3074033T1/sl unknown
- 2014-11-25 WO PCT/US2014/067393 patent/WO2015081093A1/en not_active Ceased
- 2014-11-25 CA CA2931826A patent/CA2931826C/en active Active
- 2014-11-25 DK DK14816018.7T patent/DK3074033T3/en active
-
2018
- 2018-01-23 AU AU2018200517A patent/AU2018200517B2/en not_active Ceased
-
2019
- 2019-02-05 CY CY20191100155T patent/CY1122551T1/el unknown
- 2019-12-16 JP JP2019226600A patent/JP2020059744A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513824A5 (OSRAM) | ||
| JP2015531376A5 (OSRAM) | ||
| JP2016537431A5 (OSRAM) | ||
| RU2013104401A (ru) | Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы | |
| JP2015528471A5 (OSRAM) | ||
| JP2018021046A5 (OSRAM) | ||
| JP2010077141A5 (OSRAM) | ||
| JP2016534063A5 (OSRAM) | ||
| KR20160128305A (ko) | Hbv 감염의 치료를 위한 병용 요법 | |
| CN103282021A (zh) | 炎症性疾病 | |
| JP2017523225A5 (OSRAM) | ||
| JP2017141277A5 (OSRAM) | ||
| JP2019515884A5 (OSRAM) | ||
| JP2019500387A5 (OSRAM) | ||
| KR20160032127A (ko) | 비만의 치료 | |
| JP2016514141A5 (OSRAM) | ||
| EP3068776A1 (en) | Inhibitors of influenza viruses replication | |
| JP2017508817A5 (OSRAM) | ||
| JP2017522300A5 (OSRAM) | ||
| WO2017059120A1 (en) | Compounds and combinations for the treatment of hiv | |
| JP2009513713A5 (OSRAM) | ||
| JP2009525265A5 (OSRAM) | ||
| JP2016537432A5 (OSRAM) | ||
| JP2014511897A5 (OSRAM) | ||
| JP2020533402A5 (OSRAM) |